Growth-stage biotech investors in the UK
Growth-stage companies are raising larger rounds to scale, usually led by later-stage funds, with early investors often still holding. Life sciences companies tend to raise fewer but larger rounds, often backed by university venture arms, specialist funds and Innovate UK grants. Many show a long gap between first funding and later rounds. 169 investor-backed growth-stage life sciences and biotech companies are in Pulse, and 9 raised a first funding round in the last year.
- Investor-backed companies
- 169
- Active investors, 2 years
- 1,981
- Rounds, 2 years
- 333
- Median round
- £1.91m
Who is investing
In the last two years 709 funds, firms and family offices and 1,268 angels took shares in growth-stage life sciences and biotech companies, with the latest round in Nov 2026. These are the firms backing the most of these companies:
| Firm | Type | Companies |
|---|---|---|
| British Patient Capital Limited | Fund or investment firm | 10 companies |
| The Chancellor, Masters and Scholars of the University of Oxford | University | 9 companies |
| BGF Investments | Fund or investment firm | 8 companies |
| The Chancellor, Masters and Scholars of the University of Cambridge | University | 8 companies |
| Amadeus | Fund or investment firm | 7 companies |
| Merck Ventures B.V. | Fund or investment firm | 7 companies |
| MNL Parkwalk | Fund or investment firm | 7 companies |
| Epidarex Capital III UK, LP | Fund or investment firm | 5 companies |
See all 1,981 active investors, including angels, with what they've backed, estimated cheque sizes and who they invest alongside.
Rounds and valuations
Over the last two years, 333 funding rounds were raised by growth-stage life sciences and biotech companies, an estimated £3.45bn, with a median round of about £1.91m. 9 of the companies raised their first priced round in the last 12 months. 23% of these valuations carry a High confidence rating.
How Life sciences and biotech compares
Life sciences and biotech companies make up 0% of the 74,284 investor-backed companies in Pulse. The median round of £1.91m is above the £176k median for the whole UK market. The most active firm in these companies is British Patient Capital Limited, in 10 companies.
Questions
How many investors back growth-stage life sciences and biotech companies?
Pulse found 1,981 outside investors taking shares in growth-stage life sciences and biotech companies in the last two years: 709 funds, firms and family offices, and 1,268 angels.
How much do growth-stage life sciences and biotech companies raise?
Over the last two years 333 rounds were raised, an estimated £3.45bn in total. The median round was about £1.91m.
How accurate are the amounts?
They are Pulse estimates, each with a confidence rating. 23% of recent valuations here carry a High confidence rating; the rest are marked Medium or Low.
Can I see every investor?
Pulse subscribers see every outside investor by name, with portfolios and co-investors, from £39.99 a month plus VAT (£47.99 inc. VAT). Contact details are not included and names are not linked to personal profiles.